NYC students score far below state, national averages on SAT, marking some of the lowest scores in years
Public school students in the Big Apple scored an average 473 on the math portion of last year's standardized test, which is widely used for college admissions in the US. It was a whopping 71 points below the average for the rest of New York, and 32 points below that of the rest of the country.
Reading and writing scores remained flat, with NYC students averaging 482, the same as 2023 — but the rest of the state and country again far outperformed the city, with average scores of 553 and 519, respectively.
The math, reading and writing portions of the test are each scored out of 800, making the highest possible score a 1600.
'It's another wake up call for New York City Public Schools to concentrate on improved instruction in core subjects,' remarked David Bloomfield, an educator professor at Brooklyn College and the CUNY Graduate Center.
The Big Apple's SAT flop continued a steady decline that began in 2022 and marked the lowest average cores in at least seven years, according to data released by the city Department of Education Friday.
The tests are typically administered from August through June. A school-by-school or borough breakdown was not immediately available.
Bloomfield was shocked by an especially wide gap between Asian and white test takers compared to Black and Hispanics.
Performance among each demographic on the math portion dropped in NYC compared to 2023. Asian students scored an average 582, down four points from the year before, and white students averaged a 536, down eight points from the year prior.
But Hispanic students scored an average of 430 on the math section — more than 100 points less than their white counterparts and five points less than they did the year before. Black students scored an average of 426, down two points from 2023, and 118 points lower than the rest of the state's average.
Nationally, math scores dropped by three points, and statewide, they ticked down one point.
Asian kids in NYC did better in reading and writing compared to last year, however, while white students dropped from on average of 555 to 549. Black students' reading and writing average went up slightly, from 446 to 449, while Hispanic kids' average dropped 1 point to 445.
Across the country, the reading and writing average dropped one point, while the rest of New York, not including the city, increased by one point.
'These results are a reminder that we need to keep expanding access to academic support — especially for students who haven't traditionally had it,' said Frances Kweller, director of the Manhattan- and Queens-based tutoring company Kweller Prep.
'The population of students in New York City compared to the rest of the state, compared to the rest of the country, is poorer and has more kids of color, more special ed kids and more immigrants who whose native language is other than English,' said Eric Nadelstern, who was the deputy chancellor for instruction at the DOE under former Mayor Michael Bloomberg, told The Post.
'Those are the factors that I think account for the disparity in SAT scores,' he added, noting also that students who took the test last year were starting high school when COVID-19 lockdowns hit.
NYC students' participation in the exam dropped from 71.5% of graduating students taking the exam in 2023 to 70.9% last year. The only demographic whose participation increased were Asians.
The College Board, which administers the SAT, transitioned the test to a fully digital format in the spring of 2024.
Many colleges stopped requiring SAT and ACT scores during the pandemic, but have recently reversed course.
'Colleges are moving back to 'test required' precisely because they have seen a direct correlation between SAT and ACT performance and college readiness and success,' said Linda Quarles, a Brooklyn Tech parent and vice president of the Citywide Council on High Schools.
Leo Niyazov, an 11th-grader at Brooklyn Technical High School and student at Kweller Prep, knows preparing for the SAT will up his chances of getting into West Point.
'Even though many colleges are test-optional now, West Point still requires the SAT … A strong SAT score helps strengthen my whole application,' he said.
Avish Jain, another Brooklyn Tech 11th-grader, is doing test prep in the hopes that his SAT score helps him get into college on scholarship.
'I wish more support was available in schools,' he said.
The DOE did not respond to an inquiry from The Post.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News24
14 minutes ago
- News24
‘Cultural celebration': Young Stunna's first Nigerian collab with Swayvee breaks barriers
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Show Comments ()


News24
28 minutes ago
- News24
SARS apologises as taxpayer scramble crashes eFiling site
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now Show Comments ()

Associated Press
39 minutes ago
- Associated Press
Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Illustration of TAT Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals. Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy. The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers. An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics. Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development. Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world. About Alfa Cytology Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine. Media Contact Company Name: Alfa Cytology Contact Person: Thassia C. Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals